I-Mab to Participate in Leerink Partners Global Healthcare Conference
I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision ...
Hosted on MSN2h
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform Recommendation
Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
FiercePharma17h
Leerink group goes beyond conventional metrics to evaluate cost-effectiveness of key therapies
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...
aTyr Pharma initiated with an Outperform at Leerink
Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...
Solid Biosciences Announces Pricing of Underwritten Offering
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
Vertex to Participate in Upcoming March Investor Conferences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...
Arcus Biosciences 13.6M share Secondary priced at $11.00
Goldman Sachs, Leerink and Evercore ISI acted as joint book running managers for the offering.Discover the Best Stocks and Maximize Your ...
BioPharma Dive13h
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
NeoGenomics targets 1M patients annually by 2028 with 11%-13% revenue growth in 2025
Q4 2024 . Management View. CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, ...
manilatimes9h
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
NeuroPace expects to use approximately $49.5 million of the net proceeds from the offering to repurchase 5,270,845 shares of the Company's common stock held by NeuroPace's significant stockholder, KCK ...
Solid Biosciences stock soars on promising Duchenne therapy data
The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...